双箭齐发！海南海药两款1类创新药临床研究斩获关键突破

Core Insights - Hainan Haiyao Co., Ltd. has achieved significant progress in its innovative drug development pipeline, with two new drugs reaching key clinical milestones, enhancing the company's competitive edge in the treatment of neurological and liver diseases [1] Group 1: Drug Development Progress - The drug Paenagabin, developed in collaboration with the Shanghai Institute of Materia Medica, has successfully completed Phase IIa clinical trials, showing promising results in treating focal epilepsy [2] - The Phase II clinical trial of the drug Fluofenidone, developed with Central South University, has met its primary research endpoints, indicating its potential in treating chronic hepatitis B-related liver fibrosis [4] Group 2: Clinical Trial Details - Paenagabin is a new generation KCNQ potassium channel agonist, targeting focal epilepsy that is resistant to existing treatments, with no similar products currently available globally [2][3] - The Phase II trial of Fluofenidone has established optimal dosing for reversing liver fibrosis and improving liver function, with safety profiles comparable to placebo [4][5] Group 3: Market Potential and Future Plans - There is a significant unmet clinical need in epilepsy treatment, with approximately 30% of patients not responding well to current therapies, positioning Paenagabin as a potential solution [3] - Fluofenidone has been recognized as a breakthrough therapy by the National Medical Products Administration, which may expedite its approval process [5] - Hainan Haiyao aims to expand its drug pipeline with a focus on multiple indications and targets, enhancing its research and development efforts to meet clinical demands [6][7]